Delenex Therapeutics AG Establishes Advisory Board
News Jul 26, 2014
Delenex Therapeutics AG has announced the establishment of an advisory board of seasoned executives and scientists. Seven world-renowned specialists will bring strong clinical, scientific and drug formulation expertise and assist in developing and implementing Delenex R&D strategy.
The members of the advisory board are:
Michael Detmar, M.D., Professor of Pharmacogenomics at the ETH Zurich, Switzerland. Professor Detmar is Dermatologist by training; his research work has led to a fundamental understanding of angiogenesis in skin inflammatory disorders.
Peter Elias, M.D., Professor of Dermatology at the UCSF, San Francisco, CA, USA. Prof. Elias has analyzed in depth over decades the function of the stratum corneum of the skin resulting in a novel understanding on this part of the skin.
Richard Guy, Ph.D., Professor of Pharmaceutical Sciences at the University of Bath, UK. Prof. Guy’s research focuses on skin barrier function characterization, dermal drug delivery and the assessment of skin penetration.
James G. Krueger, M.D., Ph.D., Professor of Dermatology at The Rockefeller University, New York, NY, USA. Prof. Krueger has done analyses on the regulation of immune pathways in psoriatic skin.
Thomas Luger, M.D., Ph.D., Professor of Dermatology and Chairman of the Department of Dermatology, and also the Director of the Institute of Cell Biology and Immunobiology of the Skin at Münster University, Germany. Prof. Luger’s clinical interest is focused on allergic inflammation and autoimmune diseases of the skin.
Georg Stingl, M.D., Professor and Chairman of Dermatology, Division of Immunology, Allergy & Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Austria. Prof. Stingl brings extensive experience in the regulation of skin immunology by dendritic cells and in clinical development.
Gerhard Winter Ph.D., Professor of Pharmaceutical Technology and Biopharmacy at the University of Munich, Germany. Prof. Winter’s extensive expertise is in the field of formulating proteins.
Thomas Jung, CMO at Delenex, said: “I am very much looking forward to have the opportunity to work with these prestigious experts on the further development of Delenex’ pre- and clinical products”.
“We are delighted and honored to have these internationally acknowledged leaders in dermatology and skin physiology join our advisory board,” added Thomas Hecht, Delenex Therapeutics’ Executive Chairman. “Their expertise in skin immunology and physiology will be instrumental in advancing our therapeutic programs.”